Latest Forest Laboratories (FRX) Headlines Inve
Post# of 9
Investigation Report on China's Olmesartan Market, 2009-2018: 1/3 of the World's Adults have High Blood Pressure
M2 - Fri Mar 14, 9:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z3mswh/investigation) has announced the addition of the "Investigation Report on China's Olmesartan Market, 2009-2018" report to their offering. According to statistics from WHO, one-third of the world's adults have high blood pressure. Death toll of this disease equals to half of the total number caused by stroke and heart attack. Angiotensin II receptor antagonist (ABR) is an important product among various antihypertensive drugs. Developed by Sankyo and Forest Laboratories, olmesartan medoxomil was approved to the U.S.A. in April 2002 with the trade name ""Benicar"" and was approved to Europe in October 2002. In July 2006, it was launched in Chinese market. Olmesartan can take effect very soon with low dosage, and it has strong and lasting antihypertensive effect with few adverse reactions, especially dry cough. Also because of its excellent performance worldwide, many Chinese manufacturers applied to produce the generic drug. However, this behavior caused the noted ""composition patent"" olmesartan patent infringement case in 2006, resulting in the ""Bolar Exception"" in Chinese patent system. Although Beijing Winsunny Pharmaceutical Co., Ltd. won the trial and was approved to produce the genetic drug in 2007, they violates Sankyo's patent every time they produce or sell the product. For Beijing Winsunny Pharmaceutical Co., Ltd., it has won the trial but not the market. Competition pattern of olmesartan medoxomil manufacturers from Menet indicates that olmesartan medoxomil produced by Beijing Winsunny Pharmaceutical Co., Ltd. could not go on the market until patent ZL.97126347.7 expired in 2011. As a result, market share of Beijing Winsunny Pharmaceutical Co., Ltd. is extremely low. Key Topics Covered: 1 Relevant Concepts of Olmesartan 2 Market Overview of Olmesartan in China, 2009-2013 3 Investigation on Sales Value of Olmesartan in China, 2009-2013 4 Investigation on Market Share of Major Olmesartan Manufacturers in China, 2009-2013 5 Investigation on Market Size of Olmesartan by Dosage Form in China, 2009-2013 6 Reference Price of Olmesartan Produced by Different Enterprises in China Hospital Market 7 Analysis on Major Olmesartan Manufacturers in China, 2009-2014 8 Prospect of China Olmesartan Market, 2014-2018 Companies Mentioned - Shanghai Sankyo Pharmaceutical Co., Ltd. - Beijing Winsunny Pharmaceutical Co., Ltd. - Shanghai Sine Promod Pharmaceutical Co., Ltd. For more information visit http://www.researchandmarkets.com/research/z3...estigation
Collaborations, Treatment Approvals, New Solutions, Clinical Trial Results, and New Drug Applications - Analyst Notes on Biogen Idec, Johnson & Johnson, Express Scripts, Merck, and Forest Laboratories
PR Newswire - Wed Mar 12, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Biogen Idec Inc. (NASDAQ: BIIB), Johnson & Johnson (NYSE: JNJ), Express Scripts Inc. (NASDAQ: ESRX), Merck & Co. Inc. (NYSE: MRK), and Forest Laboratories Inc. (NYSE: FRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Positive Data on Novartis' Jakavi - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 3:50PM CDT
Novartis announced positive data from a phase III trial, RESPONSE, on blood cancer drug Jakavi.
Forest Labs/Adamas Seek FDA Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 5:00PM CST
Forest Labs/Adamas files NDA for fixed-dose combination of Namenda ER/Aricept
Label Expansion for Novartis' Xolair - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 4:30PM CST
Novartis received positive news when the European Commission (EC) approved Xolair for an additional indication.
Watch for Shares of Forest Laboratories (FRX) to Approach Support at $92.62
Comtex SmarTrend(R) - Fri Mar 07, 9:36AM CST
Forest Laboratories (NYSE:FRX) has opened bearishly below the pivot of $96.45 today and has reached the first level of support at $93.90. Investors may be interested in a cross of the next downside pivot targets of $92.62 and $88.79.
Merck KGaA Misses 2013 Earnings & Rev Ests - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 9:30AM CST
Merck KGaA reported 2013 earnings per ADR of $11.70, up 19.2% year over year but below the Zacks Consensus Estimate of $11.99.
Regulatory Update on Cubist Pharma's Tedizolid - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 4:20PM CST
The EMA accepted the MAA for Cubist Pharma's tedizolid phosphate.
Encouraging Data from Roche - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 3:35PM CST
Roche (RHHBY) recently announced new encouraging data from phase IIb studies, LUTE / VERSE on asthma candidate lebrikizumab.
Patient Support Programs, Financial Results, and Stock Price Movements - Analyst Notes on Gilead, Forest Laboratories, Thermo Fisher Scientific, HCA Holdings, and Nektar
PR Newswire - Thu Mar 06, 7:25AM CST
Editor Note: For more information about this release, please scroll to bottom.